This Hormone Choice Singapore (HCS) Website has been set up by a group of concerned patients in response to a recent communication from the Singapore Ministry of Health (MOH) to Licensees/Managers of all clinics disallowing the provision of nonvidence based treatment in licensed healthcare institutions.
Letter 15 April 2014. Provision of non-evidence based treatment in licenced healthcare institutions
The letter calls attention to bioidentical hormone replacement therapy (BHRT), which we take to include natural desiccated thyroid (NDT) medication, but does not specify other forms of treatment that may be impacted by this decision.
This announcement and previous investigations by the MOH have created a great deal of uncertainty amongst doctors, patients and pharmacies about whether they can continue to use existing treatments that show considerable benefits for patients.
As a result of this uncertainty, a number of patients who could be impacted by any restriction in the use of BHRT and NDT treatment have come together to form HCS. We aim to try to find out what MOH’s letter actually means and hopefully, by showing the support for and benefits of the treatment worldwide, to convince the MOH not to remove access to the bioidentical hormone and natural thyroid treatments that we know work for us and so many people around the world like us whose symptoms are not relieved by synthetic drugs or who do not want to take synthetic drugs to relieve their symptoms.
Since all the bioidentical and desiccated thyroid hormones in Singapore are prescribed based on rigorous testing both of patients’ blood hormone levels and of the products themselves and since the treatment is endorsed by many well-known experts in other countries, following various studies, we believe there is sufficient “evidence” for their continued use. We feel much of the information on this site is extremely convincing, as is our own experience taking bioidentical hormones or desiccated thyroid, or both.
Please bookmark this website and like our Facebook page to keep up to date with the latest information on this important issue.
Share